The PREDECT project will permit the emergence of faithful models for target validation and beyond. Traditional preclinical discovery methods, particularly for target validation, poorly predict drug efficacy,
causing a high attrition rate in pharmaceutical research and development.
The PREDECT consortium will focus on complex but transferable next generation in vitro and in vivo models for breast, prostate and lung cancers. Models will be investigated for their improved potential to validate novel therapeutic targets. Known targets, in canonical pathways, will be interrogated for induction of phenotypic, proteomic and transcriptomic changes using inhibitors.
A strategy of seeking a ‘dynamic reciprocity’ of concordance between the steady and perturbed states of in vitro complex cultures, tissue slices and in vivo tumour models will be pursued by systems biology analyses. The project will develop and generate a repository of advanced complex models in 3 complementary areas:
- in vitro 2D/3D organotypic (co-)cultures, stirred bioreactor aggregates and tissue slice systems
- novel (orthotopic) grafts of human and mouse tumour samples
- genetically-engineered and mosaic mouse models.
PREDECT aims to produce results which will shift paradigms in target validation and so leading to greater predictivity of drug efficacy in drug trials. PREDECT is coordinated by Servier and AstraZeneca and the managing entity of IMI JU funding is the University of Helsinki.
The team assembles world-class biologists, clinicians and computational scientists from 8 EU institutes, 3 SMEs and 7 EFPIA members who will work to develop and then critically assess new models for target validation.
- AstraZeneca AB, Sweden
- Bayer Schering Pharma AG, Germany
- Boehringer Ingelheim International GmbH, Germany
- F. Hoffmann-La Roche AG, Switzerland
- Institut de Recherche Servier, France
- Orion Pharma, Finland
- Sigma-Tau S.p.A., Italy
UNIVERSITIES, RESEARCH ORGANISATIONS, PUBLIC BODIES & NON-PROFIT
- Catholic University Foundation, Netherlands
- Erasmus University Medical Centre, Netherlands
- Institute of Cancer Research, United Kingdom
- Ecole Polytechnique Fédérale de Lausanne, Switzerland
- Robert Bosch Society for Medical Research mbH, Germany
- Technical Research Centre of Finland
- University of Helsinki, Finland
- University of Tartu, Estonia
- Weizmann Institute of Science, Israel
- Biomedicum Genomics Ltd, Finland
- Oncotest GmbH, Germany
- Institute of Experimental Biology and Technology, Portugal
Facts & Figures
|IMI Funding||8 100 509|
|EFPIA in-kind||6 587 353|
|Other||2 532 789|
|Total Cost||17 220 651|
Institut de Recherche Servier
Rue de la République 3
Email: john.hickman [AT]fr.netgrs.com
MANAGING ENTITY OF IMI BENEFICIARIES
Emmy W. Verschuren
FIMM-EMBL International Group Leader
University of Helsinki